Patents by Inventor Luke E. Esau

Luke E. Esau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10485769
    Abstract: In one embodiment, the invention provides methods of treatment which use therapeutically effective amounts of Cholesteryl Ester Transfer Protein (CETP) inhibitors to treat a variety of cancers. In certain embodiments, the inhibitor is a CETP-inhibiting small molecule, CETP-inhibiting antisense oligonucleotide, CETP-inhibiting siRNA or a CETP-inhibiting antibody. Related pharmaceutical compositions, kits, diagnostics and screens are also provided.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: November 26, 2019
    Assignee: King Abdullah University of Science and Technology
    Inventors: Mandeep Kaur, Luke E. Esau, Sunil Sagar
  • Publication number: 20180049997
    Abstract: In one embodiment, the invention provides methods of treatment which use therapeutically effective amounts of Cholesteryl Ester Transfer Protein (CETP) inhibitors to treat a variety of cancers. In certain embodiments, the inhibitor is a CETP-inhibiting small molecule, CETP-inhibiting antisense oligonucleotide, CETP-inhibiting siRNA or a CETP-inhibiting antibody. Related pharmaceutical compositions, kits, diagnostics and screens are also provided.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 22, 2018
    Inventors: Mandeep Kaur, Luke E. Esau, Sunil Sagar
  • Patent number: 9890106
    Abstract: Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘A’ (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative ‘A’ was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative ‘A’ could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative ‘A’ highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 13, 2018
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY
    Inventors: Sunil Sagar, Mandeep Kaur, Luke E. Esau
  • Publication number: 20150368620
    Abstract: In one aspect, a method for detaching adherent cells can include adding a cell lifting solution to the media including a sample of adherent cells and incubating the sample of adherent cells with the cell lifting solution. No scraping or pipetting is needed to facilitate cell detachment. The method do not require inactivation of cell lifting solution and no washing of detaching cells is required to remove cell lifting solution. Detached cells can be stained with dye in the presence of cell lifting solution and are further analyzed using flow cytometer. The method has been tested using 6 different cell lines, 4 different assays, two different plate formats (96 and 384 well plates) and two different flow cytometry instruments. The method is simple to perform, less time consuming, with no cell loss and makes high throughput flow cytometry on adherent cells a reality.
    Type: Application
    Filed: January 29, 2014
    Publication date: December 24, 2015
    Inventors: Mandeep Kaur, Luke E. Esau